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Abstract
Background: In an aging society, the incidence and rele-
vance of rectal cancer as one of the most frequent gastroin-
testinal cancers gains in importance. Excellent surgery and 
up-to-date multimodal treatments are essential for ade-
quate oncological results and good quality of life. Summary: 
In this review, we describe modern developments in rectal 
cancer surgery and its embedment in modern multimodal 
therapy concepts. Key Message: Distinguished interdisci-
plinary cooperation combined with an outstanding surgical 
expertise is the basic requirement for an optimal treatment 
of rectal cancer. Thus, high standards of oncological out-
come and patient’s quality of life can be achieved.
© 2019 S. Karger AG, Basel
Introduction
Colorectal cancer is the third most common tumor en-
tity in Germany with an incidence of about 62,000 new 
diagnosed carcinomas every year. About one third is lo-
cated in the rectum (∼25,000/year). Although new surgi-
cal approaches and multimodal therapy strategies includ-
ing radio- and chemotherapy improved during the last 
three decades, mortality is still amongst the second (male) 
and third (female) frequent causes of cancer-related death 
in Germany [1].
Due to its localization within the rectum, rectal can-
cers are divided into tumors of the lower (0–6 cm), mid-
dle (6–12 cm), and upper (12–16 cm) third, assessed by 
rigid rectoscopy measured from the anal verge to the low-
er tumor margin. This classification is essential for the 
surgical strategy [2].
Development of Rectal Surgery: From APR to TME
In 1906, Miles established the basis for modern rectal 
cancer surgery introducing the radical “abdominoperi-
neal resection” (APR) [3]. This procedure includes a con-
ic removal of the rectum including the anus and sphinc-
ter. The APR results in creation of a permanent colosto-
my, which means, especially for younger patients, an 
enormous discomfort. Throughout the twentieth centu-
ry, the focus shifted toward sphincter-preserving surgical 
techniques and the “anterior resection” (AR) became the 
standard treatment for mid and high rectal cancer [4]. 
This therapy was limited by high rates of local recurrence 
of about 20% [5].
The introduction of the total mesorectal excision 
(TME) in 1982 by Heald et al. [6] revolutionized the un-
derstanding and success of rectal cancer surgery. This 
radical approach enables the complete resection of the 
lymphatic tissue up to the plane between the mesorectum 
and the presacral fascia (Healds “Holy Plane”) (Fig. 1, 2). 
Dissection within this avascular plane facilitated surgery 
and in parallel allows nerve- and vessel-preserving opera-
tions. This procedure, including central vessel ligation, 
became the gold standard of oncologic rectal surgery for 
tumors of the lower and middle third of the rectum. For 
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carcinomas located in the upper third, a partial mesorec-
tal excision with a safety distance of at least 5.0 cm to the 
lower tumor margin is recommended in the German S3 
guideline [2].
The precise performance of TME within the anatomi-
cal borders is essential. Especially the avoiding of “con-
ing” in case of partial mesorectal excision for high rectal 
cancers is important to ensure resection of the mesorec-
tum in a vertical plane parallel to the intestine in order 
not to leave lymphatic tissue behind.
Therefore, an exact and sharp preparation along the 
embryological, anatomical borders is mandatory to dis-
sect the mesorectum from its parietal planes (endopelvic 
fascia, parietal fascia, Denonvillier’s fascia, Waldeyer’s 
fascia). To secure a postoperative adequate sexual, ejacu-
lation, and bladder function, the surgical skills of preserv-
ing the autonomous nerves (Nn. hypogastrici, plexus hy-
pogastrici inferior and superior) are compulsive for every 
rectal surgeon. In terms of quality assurance, the rate of 
injury of the so-called “holy plane” should not exceed 5% 
in sphincter-sparing resection and 10% in APR [7, 8]. The 
circumferential resection margin (CRM) to the tumor 
should also be negative. It has been described that a CRM 
below 1 mm that can be predicted by pretherapeutic MRI 
and should be assessed by pathology leads to higher local 
recurrence rates. In case of infiltration of surrounding tis-
sue (sacral bone, prostate, seminal vesicle, uterus, vagina, 
etc.), an en-bloc resection of those adherent organs is 
mandatory, i.e., conduction of a multivisceral resection 
[9]. Since the broad introduction of TME, the rate of local 
recurrence lowered from partially > 50% to under 10% 
and consequently, overall survival improved strongly [10, 
11]. The experience of the surgeon is of essential signifi-
cance for the oncological outcome. A Swedish and Dutch 
group could detect a direct correlation of surgical experi-
ence, number of operations, and overall survival. It has 
been shown that intensive training under experienced su-
pervision can positively influence patient’s outcome [12, 
13]. Therefore, surgeons should make every effort to op-
timize the quality of surgery, as this is the factor that is of 
greatest impact for patient outcome and it has been well 
documented that experience and quality of surgery di-
rectly translate into better survival.
In addition to survival, the preservation of the anal 
sphincter plays a central role for many patients wanting 
to keep their continence. During the last 3 decades since 
the introduction of TME surgery, there has been special 
focus on sphincter-preserving operations. Low-grade tu-
mors with good or medium differentiation in the lower 
third of the rectum can be resected by keeping a safety 
margin of 1–2 cm; in case of high-grade tumors, this mar-
gin should be wider [14, 15]. After neoadjuvant radioche-
motherapy, in order to avoid APR, a distal resection mar-
gin of 0.5 cm can be acceptable when using intraopera-
tive, pathological assessment of tumor-free margins [2]. 
When evaluating the patient for sphincter-preserving 
surgery in ultra-low rectal cancer, age, patients’ medical 
history, preoperative sphincter function, and social situ-
ation should be taken into consideration. A permanent 
colonic stoma can sometimes be more convenient than a 
malfunctioning anal sphincter. If possible, the internal 
anal sphincter muscle can be partially or completely re-
moved, i.e., an intersphincteric rectal resection can be 
performed, with results of complete continence in over 
50% of cases combined with acceptable oncologic out-
comes [16, 17].
After rectal resection, the reservoir function of the am-
pulla is limited with high rates of urge incontinence. 
Many efforts have been made to reduce this phenomenon 
by the development of diverse types of alternative reser-
voirs. Upon those, transverse coloplasty and J-pouch are 
the widely used alternatives [18]. In addition, the use of 
linear and circular stapling devices helped to reduce the 
rate of anastomotic insufficiency [19] (Fig. 3).
In case of tumor infiltration of the anal channel, the 
external anal sphincter, or levator, a zylindric APR, in-
Fig. 1. Open TME. Fig. 2. TME with pelvic nerve plexus.
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cluding resection of the levatoric muscles, should be pre-
ferred instead of conventional conic APR (Fig.  4). Al-
though there is a high rate of local, surgical site infections, 
patients’ survival significantly increases when using this 
more radical approach [20, 21].
Patients presenting with stenosing tumors and acute 
ileus symptoms should receive a primary approach of a 
diverting stoma preferentially by laparoscopic technique 
in the sigma or distal ileum followed by staging, potential 
neoadjuvant therapy, and elective tumor surgery.
Minimally Invasive Surgery
The aim in almost all areas of surgery is to be highly 
effective with simultaneously causing as less tissue trau-
ma as possible to reduce negative side effects and improve 
patients’ outcome. Since establishment of laparoscopic 
techniques, minimally invasive procedures have been in-
creasingly introduced in all areas of oncologic surgery. 
Advantages compared to conventional techniques are 
faster mobilization after surgery due to lower pain rates 
and lower need of analgesic medication, especially opi-
oids, reduced blood loss, shorter in-hospital stay, lower 
rates of cardiac and pulmonary complications, lower 
rates of surgical site infections, and lower rates of inci-
sional hernias and intestinal obstruction [22]. For onco-
logic rectal resection, a clearly reduced 30-day mortality 
rate has been shown [23, 24]. However, similar to open 
surgery, surgical experience is important for results, com-
plication rates, and oncologic outcome. Several studies 
(e.g., COLOR II trial) demonstrated similar long-term 
overall and disease-free survival rates for laparoscopic 
versus open rectal carcinoma resection [2, 24, 25]. The 
latest development of minimal invasive rectal surgery, ro-
botic surgery, is described separately within this issue.
Further innovation in minimally invasive rectal sur-
gery is the concept of transanal TME (TATME). TATME 
is proposed in highly selected cases as an alternative ap-
proach or in addition to laparoscopic, robotic, or open 
dissection of the rectum via the abdominal approach 
(Fig. 5). The aim of this novel procedure is to overcome 
limitations and facilitate standard laparoscopic TME. A 
time-saving double team approach can be applied by 
combining transanal with transabdominal endoscopic 
techniques. First retrospective data seem to have lower 
rates of positive circumferential resection margins. The 
authors describe no higher complication rates compared 
to standard TME. However, results of randomized con-
trolled trials and long-term survival rates of this tech-
nique are still not available [26].
Neoadjuvant Therapy
In deep and middle rectal carcinomas with T3/4 or N+, 
a preoperative radiation with fractioned application of 
45.0–50.4 Gy plus chemotherapy (intravenous or oral 
5-fluorouracil) is recommended in current international 
guidelines. This aims at a “downstaging” of the tumor to 
enable sphincter-preserving resections and at the reduc-
tion of local recurrence. After 6–8 weeks of recovery, elec-
tive operation should be performed. If the tumor size re-
duction is not in focus, a short-term radiation protocol 
with 5 × 5 Gy application scheme is possible followed by 
immediate operation within 10 days after the first radia-
Fig. 3. Distal rectum ready for anastomosis.
Fig. 4. Cylindric APR specimen.
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tion. This also reduced the rate of local recurrence signif-
icantly, but in total, radiotherapy does not improve pa-
tient’s overall survival [27]. The price for the lower rate of 
local recurrence is a higher perioperative morbidity (in-
continence, sexual dysfunction, urinary incontinence, hip 
fractures, secondary tumors) and social restrictions [28]. 
Patients with T1/2 tumors and questionable lymph node 
metastasis as well as patients with T3a/b tumors of the 
middle rectum and limited perirectal infiltration in MRI 
(T3a < 1 mm; T3b 1–5 mm) without suspicious lymph 
nodes or extramural vessel invasion can be treated by sur-
gery primarily [2]. The circumferential resection margin 
from the mesorectal fascia measured in MRI should actu-
ally not be a decision-maker for direct surgery according 
to German S3 guidelines, but seems to be promising for 
future decision-making avoiding side effects of radiother-
apy (MERCURY II trial) [29, 30]. Recently, a prospective 
multicenter observational study (OCUM Rectal Cancer 
Trial) could demonstrate that the restriction of neoadju-
vant chemoradiotherapy only to high-risk patients 
achieves good results dependent on the MRI-measured 
distance of the tumor to the mesorectal fascia [31].
Rectal carcinomas of the upper third should be resect-
ed generally without any neoadjuvant treatment. In those 
cases, neoadjuvant therapy should only be applied in risk 
situations (T4, CRM+, clearly lymph node+) [2].
Watch-and-Wait Policy versus Standard Resection
TME significantly reduces the risk of local recurrence 
in rectal cancer patients. In combination with neoadju-
vant radiotherapy or radiochemotherapy, the recurrence 
rate can be diminished and sphincter-preserving surgery 
can be increased in selected patients with lower locally 
advanced rectal cancer. The advances of a radical onco-
logic resection faces the risk of an up to 5% perioperative 
mortality and severe complications such as anastomotic 
leakage, sexual, bladder, and bowel dysfunction, or a per-
manent colostomy [32, 33].
More than a decade ago, reports came up that de-
scribed a complete treatment response after neoadjuvant 
radiochemotherapy [34]. Those reports raised the ques-
tion of an organ-preserving alternative to the established 
resectional rectal surgery after neoadjuvant treatment 
with an equivalent oncologic outcome. A recent meta-
analysis showed an incidence of complete clinical re-
sponse of 22.4% with a 3-year cumulative risk of local 
regrowth of 21.6% [35]. In almost 90% of these patients, 
salvage surgery was performed with a 3-year overall sur-
vival of 93.5%. Thus, the authors conclude that a watch-
and-wait policy for patients with complete response fol-
lowing neoadjuvant radiochemotherapy appears feasible 
and safe without an increase in the risk of systematic dis-
ease or adverse survival outcomes.
As the effect of neoadjuvant radiation is obviously de-
pendent on tumor stage, a potential benefit of neoadju-
vant chemoradiation in early rectal cancers is under con-
troversial discussion. Excellent oncological outcomes of 
TME surgery face the uncertain advances of watch-and-
wait strategies in cases of complete response after neoad-
juvant therapy. In a retrospective analysis, the Sao Paulo 
group recently published 57% complete response rates 
for standard and even 86% for an extended chemoradia-
tion regime on T2N0 rectal cancer patients [36]. How-
ever, this and other studies neglect the relevance of long-
term side effects of chemoradiotherapy. It has been shown 
that long-term functional problems such as bowel or sex-
ual disorders are significantly increased among patients 
having neoadjuvant chemoradiation compared with pa-
tients having surgery alone [28]. Underlying the above-
average rates of complete responses in the Brazilian data, 
a relevant number of patients still needs salvage surgery 
facing the above-mentioned side effects of surgery and 
chemoradiation. Therefore, and considering the promis-
ing results of studies such as the OCUM trial [31], we 
propose to rather curtail the frequency of neoadjuvant 
therapy than to expand the incidence to a larger group of 
patients. However, in patients who develop a complete 
response to neoadjuvant chemoradiation in locally ad-
vanced tumors, watch-and-wait seems to be a valid alter-
native, even though this notion has not be formally tested 
in randomized controlled trials.
Adjuvant Therapy
After surgery and receiving the final pathologic TNM 
stage, adjuvant therapy should be evaluated in interdisci-
plinary tumor boards. In case of T1/2 N0 rectal cancer, no 
adjuvant therapy is recommended. For patients with risk 
factors for local recurrence (R1, tumor perforation, poor 
Fig. 5. Transanal TME.
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TME quality, pT4, pT3c/d, pN2, extranodal tumor spots 
in the mesorectum, pT3 in lower rectum), adjuvant che-
motherapy within 8 weeks after surgery is standard ther-
apy in Germany. However, a formal proof by randomized 
studies is still lacking. High rectal tumors should be treat-
ed analogous to colonic carcinomas [2].
Therapy Concepts in Local Recurrence and 
Metastatic Disease
Local Recurrence
The treatment of local recurrence depends on the ther-
apy regimen given for primary tumor. In patients who did 
not receive neoadjuvant chemoradiation at initial treat-
ment, the recurrent tumors should first undergo this 
therapy prior to surgery. In case of primary neoadjuvant 
radiation/chemotherapy and a possibility reaching R0 re-
section, direct surgery is recommended. In case of pri-
mary neoadjuvant-treated patients and borderline resect-
ability, an individual concept between oncologist, radio-
therapist, and surgeon is necessary that takes into account 
the intensity of previous therapy and the patients’ history 
and current health situation. Surgical aspects should con-
centrate on reaching an R0 situation, which often can 
only be achieved by pelvic exenteration, including the re-
moval of surrounding tissue (bladder, bone, vagina, uter-
us, nerves, vessels, etc.) (Fig. 6a, b). These operations are 
often followed by high rates of morbidity (> 30%) and low 
30-day mortality (∼2%), including loss of sexual, sphinc-
ter, and urinary function. Risk factors for worse outcome 
are positive resection margins and bone resection [2, 37, 
38].
Peritoneal Carcinomatosis
In case of limited peritoneal carcinomatosis without 
extra-abdominal metastasis, a complete cytoreductive 
surgery (removal of all visible tumor spots, complete tu-
mor debulking) followed by hypertermic, intraperitoneal 
chemotherapy (HIPEC) can be performed. This leads to 
overall survival rates of > 50% in 5 years, which is supe-
rior to palliative chemotherapy. Patients benefit signifi-
cantly more with a peritoneal carcinomatosis index (PCI) 
< 11 than patients with PCI < 20 [39–41]. Recent results of 
the Unicancer Prodige 7 trial, however, shed some doubt 
on this notion, as survival was not improved by HIPEC in 
this study.
Liver/Lung Metastasis
Patients in a metastatic situation should always be 
evaluated interdisciplinary in the presence of an expe-
rienced thoracic/liver surgeon, as surgery is the only 
curable therapy option. Limited metastatic disease can 
be cured by resection along the anatomic borders of 
lung and liver. If in doubt for resection, a “downsizing” 
with neoadjuvant chemotherapy using novel therapy 
regimens and antibodies can lead to secondary opera-
bility. To reduce postoperative liver failure (small-for-
size-syndrome), new approaches are available which 
lead to a growth-allurement of the healthy part of the 
liver. The application of these techniques offers the pos-
sibility to resect initially unresectable liver metastases 
in curable intention. Those procedures like portal vein 
ligation, associating liver partition, and portal vein liga-
tion for staged hepatectomy (ALPPS) only should be 
performed in high-volume centers. Cases with infiltra-
tion of surrounding tissues or big vessels in need for 
complex reconstructions must be evaluated individu-
ally taking into account age, fitness, medical history, 
and residual volume of liver/lung. To summarize, met-
astatic surgery is always a compromise between the 
technical possibilities and the will and personal situa-
tion of the patient.
a b
Fig. 6. a Local recurrence (PET scan). b Resection of local recurrence with preservation of pelvic plexus.
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Optimizing Perioperative Setting
In times of aging patients, an optimal perioperative 
setting is inevitable in order to reduce patients’ morbidity 
and mortality and to reduce costs. Before addressing the 
patient to surgery, a tumor-caused anemia due to defi-
ciency of iron can be assessed easily and substituted re-
ducing the perioperative transfusion of packed red blood 
cells (PRBC). The use of PRBC is associated with elevated 
morbidity and mortality [42]. Furthermore, the nutri-
tional status of every patient should be evaluated by using 
a nutritional risk score (NRS). Dependent on this score, 
additional alimentation might lead to reduced periopera-
tive complications due to hypoalbuminemia [43].
In times of fast-track surgery, preoperative mechanical 
bowel preparation before colorectal operations has been 
reduced to a minimum. Recent trials showed an advan-
tage of mechanical bowel preparation and selective de-
contamination of the digestive tract in elective colorectal 
surgery to reduce collagenase-producing microbiome 
and thus, reduce the rate of anastomotic leakage and 
wound infections [44–46]. In our department, patients 
receiving elective rectal resection obtain mechanical bow-
el preparation and are treated with oral and rectal antibi-
otics perioperatively.
Furthermore, the World Health Organization recom-
mends a number of perioperative procedures to reduce 
perioperative morbidity. Those include preoperative 
showering/bathing with (antibacterial) soap, reducing 
immunosuppressive medication, shaving hair by using 
hair clipping, preoperative antibiotic prophylaxis 30–60 
min before surgery starts, keeping normothermia during 
operation, cleaning of the umbilicus, proper skin disin-
fection, use of stapling devices, proper change of gloves 
and instruments, and use of antibiotic-eluted suture ma-
terial [47].
Modern cancer patient management furthermore in-
cludes psycho-oncological support as well as instruction 
and training in the use of the stoma care during hospital 
stay. Mobilization and respiratory muscle training should 
be standardized and performed under physiotherapeutic 
supervision as part of an “Enhanced Recovery After Sur-
gery” (ERAS) program, which includes further measures.
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